According to Invitae 's latest financial reports and stock price the company's current Operating Margin is -610.33%. At the end of 2021 the company had an Operating Margin of -90.32%.
Year | Operating Margin | Change |
---|---|---|
2021 | -90.32% | -64.65% |
2020 | -255.46% | 112.7% |
2019 | -120.10% | 34.23% |
2018 | -89.48% | -51.26% |
2017 | -183.57% | -54.14% |
2016 | -400.26% | -62.65% |
2015 | -1,071.64% | -63.81% |
2014 | -2,960.85% | -82.36% |
2013 | -16,782.43% |
Company | Operating Margin | Operating Margin differencediff. | Country |
---|---|---|---|
Celldex Therapeutics CLDX | -1,520.92% | 149.20% | ๐บ๐ธ USA |
HTG Molecular Diagnostics
HTGM | -326.08% | -46.57% | ๐บ๐ธ USA |
CareDx CDNA | -24.00% | -96.07% | ๐บ๐ธ USA |
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.